Reviewing Immunome (IMNM) & Its Competitors

Immunome (NASDAQ:IMNM – Get Free Report) is one of 842 public companies in the “Biotechnology” industry, but how does it weigh in compared to its rivals? We will compare Immunome to related companies based on the strength of its dividends, analyst recommendations, profitability, valuation, risk, institutional ownership and earnings.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Immunome and its rivals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Immunome 1 1 14 0 2.81
Immunome Competitors 9926 15341 45743 1601 2.54

Immunome presently has a consensus target price of $33.85, indicating a potential upside of 103.77%. As a group, “Biotechnology” companies have a potential upside of 110.59%. Given Immunome’s rivals higher possible upside, analysts clearly believe Immunome has less favorable growth aspects than its rivals.

Volatility and Risk

Immunome has a beta of 2.68, meaning that its stock price is 168% more volatile than the S&P 500. Comparatively, Immunome’s rivals have a beta of -1.85, meaning that their average stock price is 285% less volatile than the S&P 500.

Insider & Institutional Ownership

44.6% of Immunome shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 7.2% of Immunome shares are held by insiders. Comparatively, 13.2% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Immunome and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Immunome N/A -51.33% -47.63%
Immunome Competitors -12,516.26% -215.37% -31.41%

Earnings & Valuation

This table compares Immunome and its rivals revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Immunome $6.94 million -$212.39 million -6.29
Immunome Competitors $718.90 million $8.79 million -18.37

Immunome’s rivals have higher revenue and earnings than Immunome. Immunome is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Summary

Immunome rivals beat Immunome on 7 of the 13 factors compared.

Immunome Company Profile

(Get Free Report)

Immunome is a biotechnology company focused on discovering and developing therapies for cancer. It uses an antibody-discovery platform to identify targets and develop medicines intended to address areas of significant unmet medical need. The company’s research and development programs include targeted cancer treatments, such as antibody-based therapies and other drug candidates. Its portfolio has included investigational medicines for solid tumors and other cancers; these products are in development and are not necessarily approved for commercial use.

Receive News & Ratings for Immunome Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunome and related companies with MarketBeat.com's FREE daily email newsletter.